4D Molecular Therapeutics, Inc. (FDMT) Ownership
FDMT ownership summary
as of October 18, 2026- Institutions
- 106.1% of shares outstanding
- Insiders
- 2.72% of shares outstanding
- Shares outstanding
- 55.2M
- Float
- 42.6M shares available to trade
- Short interest
- 23.32% 11.2M shares short
- Days to cover
- 11.58 short interest down 6.4% vs prior month
- Institutions 106.08%
- Insiders 2.72%
FDMT top institutional holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Jupiter Topco LLC | 10.40% | 5.7M | $69.8M | +5.7M (0.0%) | June 30, 2026 |
| 2 | HHG PLC | 9.50% | 5.2M | $63.7M | +611,276 (+13.2%) | March 31, 2026 |
| 3 | RA Capital Management, LLC | 9.14% | 5.0M | $61.3M | — | June 30, 2026 |
| 4 | BlackRock Inc | 8.23% | 4.5M | $55.2M | +400,756 (+9.7%) | June 30, 2026 |
| 5 | The Goldman Sachs Group Inc | 7.71% | 4.3M | $51.7M | +53,230 (+1.3%) | June 30, 2026 |
| 6 | Novo A/S | 5.88% | 3.2M | $39.4M | −401,559 (−11.0%) | June 30, 2026 |
| 7 | State Street Corp | 5.27% | 2.9M | $35.3M | +203,234 (+7.5%) | June 30, 2026 |
| 8 | Bvf Inc | 5.21% | 2.9M | $35.0M | — | June 30, 2026 |
| 9 | T. Rowe Price Investment Management,Inc. | 4.55% | 2.5M | $30.5M | +2.5M (0.0%) | June 30, 2026 |
| 10 | Adage Capital Partners Gp LLC | 4.07% | 2.2M | $27.3M | +644,047 (+40.1%) | June 30, 2026 |
| 11 | Trails Edge Capital Partners, LP | 4.03% | 2.2M | $27.0M | +925,000 (+71.0%) | June 30, 2026 |
| 12 | Vanguard Capital Management, LLC | 3.80% | 2.1M | $25.5M | −96,523 (−4.4%) | June 30, 2026 |
| 13 | Armistice Capital, LLC | 3.62% | 2.0M | $24.3M | — | June 30, 2026 |
| 14 | Geode Capital Management, LLC | 2.04% | 1.1M | $13.7M | +63,121 (+5.9%) | June 30, 2026 |
| 15 | Bank of America Corp | 2.03% | 1.1M | $13.6M | +146,501 (+15.0%) | June 30, 2026 |
| 16 | Parkman Healthcare Partners LLC | 1.72% | 948K | $11.5M | +425,607 (+81.4%) | June 30, 2026 |
| 17 | Dimensional Fund Advisors, Inc. | 1.32% | 731K | $8.9M | +208,034 (+39.8%) | June 30, 2026 |
| 18 | Deutsche Bank AG | 1.29% | 711K | $8.6M | +2,898 (+0.4%) | June 30, 2026 |
| 19 | Citadel Advisors Llc | 1.24% | 688K | $8.3M | +423,501 (+160.4%) | June 30, 2026 |
| 20 | Renaissance Technologies Corp | 1.11% | 615K | $7.5M | +36,308 (+6.3%) | June 30, 2026 |
Value at the latest close. Change = shares bought or sold in the latest quarterly filing (13F). In the top 20, 15 holders added 12.4M shares and 2 cut 498K.
FDMT top mutual fund and ETF holders
20 largest| # | Holder | % of shares | Shares | Value | Change | Reported |
|---|---|---|---|---|---|---|
| 1 | Vanguard MStar Total Stk Mkt Idx Invest | 2.88% | 1.6M | $19.3M | — | August 31, 2026 |
| 2 | iShares Russell 2000 ETF | 2.15% | 1.2M | $14.4M | −13,696 (−1.1%) | September 30, 2026 |
| 3 | State Street® SPDR® S&P® Biotech ETF | 2.14% | 1.2M | $14.4M | −22,600 (−1.9%) | September 30, 2026 |
| 4 | T. Rowe Price Small-Cap Stock | 1.66% | 917K | $11.1M | −610 (−0.1%) | August 31, 2026 |
| 5 | Janus Henderson Hrzn Biotec E2 USD | 1.64% | 905K | $11.0M | −79,834 (−8.1%) | June 30, 2026 |
| 6 | Janus Henderson Global Life Sciences D | 1.57% | 865K | $10.5M | +76,973 (+9.8%) | August 31, 2026 |
| 7 | Janus Henderson Glb Life Scn I2 USD | 1.52% | 838K | $10.2M | +44,690 (+5.6%) | August 31, 2026 |
| 8 | Janus Global Life Science AUSD | 1.44% | 793K | $9.6M | +10,190 (+1.3%) | June 30, 2026 |
| 9 | Fidelity Small Cap Index | 0.91% | 502K | $6.1M | +5,238 (+1.1%) | July 31, 2026 |
| 10 | T. Rowe Price Instl Small-Cap Stock | 0.90% | 498K | $6.0M | — | August 31, 2026 |
| 11 | T. Rowe Price Small-Cap Value | 0.78% | 431K | $5.2M | −3,953 (−0.9%) | August 31, 2026 |
| 12 | iShares Russell 2000 Value ETF | 0.78% | 429K | $5.2M | +650 (+0.2%) | September 30, 2026 |
| 13 | iShares Biotechnology ETF | 0.71% | 391K | $4.7M | −2,960 (−0.8%) | September 30, 2026 |
| 14 | Xtrackers S&P 500 Swap ETF 1C | 0.56% | 308K | $3.7M | −2,274 (−0.7%) | December 31, 2025 |
| 15 | Stt Strt®SPDR®S&PKenshoNwEcosComposETF | 0.50% | 274K | $3.3M | — | September 30, 2026 |
| 16 | Nuveen Quant Small Cap Equity R6 | 0.49% | 272K | $3.3M | −116,300 (−29.9%) | August 31, 2026 |
| 17 | Vanguard Russell 2000 ETF | 0.48% | 263K | $3.2M | +6,100 (+2.4%) | August 31, 2026 |
| 18 | JPM Thmtcs Gentc Thrps C2 dist USD | 0.43% | 238K | $2.9M | +2,670 (+1.1%) | August 31, 2026 |
| 19 | Schwab US Small-Cap ETF™ | 0.42% | 230K | $2.8M | +153 (+0.1%) | September 30, 2026 |
| 20 | Fidelity Enhanced Small Cap Core ETF | 0.40% | 222K | $2.7M | +465 (+0.2%) | September 30, 2026 |
Funds report holdings monthly or quarterly; dates differ by fund.
FDMT insider transactions
latest 8| Date | Name | Transaction | Price | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-20 | Ashoo Gupta | Sell | $8.61 | 390 | $3,358 |
| 2025-12-20 | Ashoo Gupta | Sell | $8.68 | 389 | $3,377 |
| 2025-12-16 | Scott Bizily | Sell | $10.90 | 1,635 | $17,822 |
| 2025-11-17 | Scott Bizily | Sell | $10.59 | 1,635 | $17,315 |
| 2025-10-24 | Scott Bizily | Sell | $12.00 | 2,678 | $32,136 |
| 2025-10-16 | Scott Bizily | Sell | $10.17 | 1,635 | $16,628 |
| 2025-10-09 | Scott Bizily | Sell | $10.00 | 2,408 | $24,080 |
| 2025-09-23 | Scott Bizily | Sell | $8.00 | 2,407 | $19,256 |
Reported trades by company officers, directors and other filers (including disclosures by members of Congress where EODHD lists them). "—" where the filing gives no share count.
FDMT shares outstanding
Year-end shares outstanding, adjusted for splits.
Who owns FDMT
Institutional investors own 106.1% of 4D Molecular Therapeutics's shares and insiders 2.72%. The largest holder is Jupiter Topco LLC with 10.40% of the shares (5.7M), as of June 30, 2026. Among the top 20 institutions, 15 added shares and 2 reduced their stake in the latest filings. Short interest is 23.32% of the float, or 11.58 days of average trading volume. The share count rose 1,040.9% since 2018.
Related: FDMT analyst forecast, FDMT key metrics. See the FDMT stock overview for the latest quote and news.
FDMT ownership FAQ
Who owns the most 4D Molecular Therapeutics stock?
The largest shareholders of 4D Molecular Therapeutics are Jupiter Topco LLC (10.40%), HHG PLC (9.50%), RA Capital Management, LLC (9.14%), BlackRock Inc (8.23%), The Goldman Sachs Group Inc (7.71%).
What percentage of 4D Molecular Therapeutics is owned by institutions?
Institutions hold 106.1% of 4D Molecular Therapeutics's shares outstanding; insiders hold 2.72%.
Which funds own 4D Molecular Therapeutics?
The largest fund holders of 4D Molecular Therapeutics are Vanguard MStar Total Stk Mkt Idx Invest (2.88%), iShares Russell 2000 ETF (2.15%), State Street® SPDR® S&P® Biotech ETF (2.14%), T. Rowe Price Small-Cap Stock (1.66%), Janus Henderson Hrzn Biotec E2 USD (1.64%).
What is 4D Molecular Therapeutics's short interest?
11.2M shares of 4D Molecular Therapeutics were sold short, 23.32% of the float; at the average daily volume it would take 11.58 days to cover.
Are insiders buying or selling 4D Molecular Therapeutics?
Of the latest 8 reported insider transactions in 4D Molecular Therapeutics (since September 23, 2025), 0 were purchases and 8 were sales.
How many shares of 4D Molecular Therapeutics are outstanding?
4D Molecular Therapeutics has 55.2M shares outstanding, of which 42.6M are in the public float.